High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013 LEARN MORE>
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013
>Go!

Pharmaceuticals

Actavis develops, manufactures and markets generics, branded generics, established brands and Over-the-Counter (OTC) products in more than 60 countries around the world.

The third-largest generic pharmaceutical company in the United States with approximately 10 percent market share, Actavis is also in the top 3 in approximately 12 global markets, the top 5 in approximately 16 global markets and in the top 10 in approximately 33 global markets.

Actavis’ global branded pharmaceutical business is focused principally in the Women's Health and Urology therapeutic categories, as well as Gastroenterology and Dermatology in the United States.

Internationally, we are also expanding our branded pharmaceutical business into Canada and Latin America, and pursuing opportunities to expand in other key markets.

Local Products
Australia ( English )
Austria ( German )
Bosnia and Herzegovina ( Bosnian )
Brazil ( Portuguese )
Bulgaria ( Bulgarian )
Canada Generics ( English, French )
Canada Specialty ( English, French )
Czech Republic ( Czech )
Denmark ( Danish )
Finland ( Finnish )
Hong Kong ( English, Chinese )
Hungary ( Hungarian )
Iceland ( Icelandic )
Indonesia ( Bahasa )
Ireland ( English )
Japan ( Japanese )
Lithuania ( Lithuanian )
Malaysia ( English )
Malta ( English )
Mongolia ( Mongolian )
New Zealand ( English )
Norway ( Norwegian )
Poland ( Polish )
Romania ( Romanian )
Russia ( Russian )
Serbia ( Serbian )
Singapore ( English )
Slovenia ( Slovenian )
Sweden ( Swedish )
Switzerland ( German, French )
Turkey ( Turkish )
UK ( English )
Ukraine ( Ukrainian )
US ( English )